Coherus Oncology, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports the results of the 2026 Annual Meeting of Stockholders held by Coherus Oncology, Inc. on May 27, 2026. The meeting was conducted virtually. The meeting was partially adjourned to May 29, 2026, specifically to address voting on Proposal 4, a non-routine matter. As of the record date on April 16, 2026, there were 154,217,609 shares of common stock outstanding.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and stockholder voting outcomes.
Material Changes and Voting Results
The following proposals were voted upon by stockholders:
- Proposal 1 (Election of Directors): Stockholders elected Dennis M. Lanfear and Mats L. Wahlström as Class III directors to serve until the 2029 annual meeting.
- Proposal 2 (Auditor Ratification): Stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- Proposal 3 (Say-on-Pay): Stockholders approved a non-binding advisory resolution regarding the compensation of named executive officers.
- Proposal 4 (Stock Option Price Reduction): Stockholders approved the reduction in the exercise price of certain outstanding stock options. This vote occurred on May 29, 2026, with 45,996,610 votes cast in favor and 45,362,110 against.
- Proposal 5 (Equity Plan Increase): Stockholders approved an increase in the number of shares of common stock reserved for issuance under the Amended and Restated 2014 Equity Incentive Award Plan.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, or contingencies beyond the standard disclosure of the voting process and the adjournment of the meeting for Proposal 4.
Key Facts for Investor Verification
- Verify the specific terms and financial impact of the approved reduction in stock option exercise prices (Proposal 4).
- Confirm the exact number of additional shares authorized under the Amended and Restated 2014 Equity Incentive Award Plan (Proposal 5).
- Review the Definitive Proxy Statement on Schedule 14A filed on April 20, 2026, and the Supplement filed on May 28, 2026, for detailed proposal descriptions.
- Note that Proposal 4 was a close vote, with a narrow margin between "For" and "Against" votes.